Baidu
map

CDS 2015:MedSci专访许樟荣教授:糖尿病足预防及分级管理

2015-12-15 MedSci MedSci原创

2015年12月9日—12日,由中华医学会、中华医学会糖尿病学分会(CDS)主办,江苏省医学会承办的“中华医学会糖尿病学分会第十九次全国学术会议(CDS 2015)”在苏州国际博览中心举行。 梅斯医学(MedSci)有幸采访了中国人民解放军第 306 医院全军糖尿病诊治中心主任许樟荣教授。 MedSci:许教授,您好!感谢您接受MedSci的采访。您在今年第七届国际糖尿病足大会上作为中国唯

2015年12月9日—12日,由中华医学会、中华医学会糖尿病学分会(CDS)主办,江苏省医学会承办的“中华医学会糖尿病学分会第十九次全国学术会议(CDS 2015)”在苏州国际博览中心举行。

梅斯医学(MedSci)有幸采访了中国人民解放军第 306 医院全军糖尿病诊治中心主任许樟荣教授。

MedSci:许教授,您好!感谢您接受MedSci的采访。您在今年第七届国际糖尿病足大会上作为中国唯一代表参与了5部指南的定制,在今天的CDS大会上您也分我们分享了与糖尿病足病的综合治疗以及分级管理相关议题,请您简单跟我们分享一下关于糖尿病足病的综合治疗上您的个人心得。

许樟荣教授:糖尿病足病是糖尿病慢性并发症之一,治疗困难而且医疗费用高,预后差,在糖尿病足病的综合治疗中,不能简单的只看重血糖管理,一定要做到全身治疗包括血糖血压控制、血脂调整及患者营养支持与合理运动等。糖尿病足病大多发生在病程长的老年糖尿病患者,并且是多种微信因素共同作用的结果,主要原因为周围神经病、周围血管病和感染。根据2015年发布《糖尿病足预防指南》,我们应当积极处理足部溃疡前期病变,如去除胼胝、足部水泡的保护和处理,去除向皮肤内生长及变厚的脚趾甲,处理足部局部出血,抗真菌感染治疗。糖尿病足防治非常重要,有80%以上的糖尿病足溃疡是可以预防的,要提高医生和患者的预防意识,尽量不让患者不发生糖尿病足病。

MedSci:那么对于糖尿病分级管理,您有怎样的心得体会?

许樟荣教授:糖尿病足病的分级管理的目的主要是对损伤的标准描述和提出比较规范的治疗,每一种评价体系都有待完善,在基层医院主要以预防为主;二级医院可以对不严重糖尿病患者进行治疗以及教育科普;有条件的医院可以对溃疡高危因素的患者进行检查,包括血管,神经系统,皮肤和足结构。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703205, encodeId=f75d1e03205b1, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sun Dec 27 05:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48431, encodeId=0a87484311e, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:04:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377596, encodeId=6d3a13e7596f5, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Thu Dec 17 04:30:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606770, encodeId=caf31606e7019, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Dec 17 04:30:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46338, encodeId=bc454633828, content=。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35d51668872, createdName=zhgangxy, createdTime=Tue Dec 15 23:55:00 CST 2015, time=2015-12-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1703205, encodeId=f75d1e03205b1, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sun Dec 27 05:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48431, encodeId=0a87484311e, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:04:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377596, encodeId=6d3a13e7596f5, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Thu Dec 17 04:30:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606770, encodeId=caf31606e7019, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Dec 17 04:30:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46338, encodeId=bc454633828, content=。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35d51668872, createdName=zhgangxy, createdTime=Tue Dec 15 23:55:00 CST 2015, time=2015-12-15, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    好文章,值得看。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1703205, encodeId=f75d1e03205b1, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sun Dec 27 05:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48431, encodeId=0a87484311e, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:04:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377596, encodeId=6d3a13e7596f5, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Thu Dec 17 04:30:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606770, encodeId=caf31606e7019, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Dec 17 04:30:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46338, encodeId=bc454633828, content=。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35d51668872, createdName=zhgangxy, createdTime=Tue Dec 15 23:55:00 CST 2015, time=2015-12-15, status=1, ipAttribution=)]
    2015-12-17 yangpeizhi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1703205, encodeId=f75d1e03205b1, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sun Dec 27 05:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48431, encodeId=0a87484311e, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:04:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377596, encodeId=6d3a13e7596f5, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Thu Dec 17 04:30:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606770, encodeId=caf31606e7019, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Dec 17 04:30:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46338, encodeId=bc454633828, content=。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35d51668872, createdName=zhgangxy, createdTime=Tue Dec 15 23:55:00 CST 2015, time=2015-12-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1703205, encodeId=f75d1e03205b1, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sun Dec 27 05:30:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48431, encodeId=0a87484311e, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:04:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377596, encodeId=6d3a13e7596f5, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Thu Dec 17 04:30:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606770, encodeId=caf31606e7019, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Dec 17 04:30:00 CST 2015, time=2015-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46338, encodeId=bc454633828, content=。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35d51668872, createdName=zhgangxy, createdTime=Tue Dec 15 23:55:00 CST 2015, time=2015-12-15, status=1, ipAttribution=)]
    2015-12-15 zhgangxy

    。。。

    0

相关资讯

EASD 2013:糖尿病足患者的院前延迟的影响因素及后期护理质量

来自中国的B. Zhou在9月23日至27日召开的欧洲糖尿病研究学会(EASD)第49届年会上报告,此研究旨在调查糖尿病足患者延迟就医的比例,及可能的危险因素及预后。研究指出,在患者组中存在以下已知因素者长院前延迟最明显:无前期病史、社会经济水平低、足部检查稀少、无随访、从未接受过糖尿病足相关教育及缺乏糖尿病足相关知识;且这些因素所导致的延迟与患者较差的转归、下肢截肢和死亡明显相关。针对危险群体应

图解:糖尿病足的临床护理

糖尿病足病是糖尿病最严重的慢性并发症之一,严重影响患者的生活质量,威胁到患者的肢体健全,重者可导致截肢。对于糖尿病患者,其下肢截肢的相对风险是非糖尿病患者的40倍。而我国三甲医院非创伤性截肢患者中约有1/3为糖尿病所致。 周秋红老师认为,临床应重视糖尿病足病并给予充分护理。在这里,周老师首先为大家讲解了糖尿病足病的基础知识: 糖尿病足病的定义 指糖尿病患者因下肢远端神经异常和外周血管

李炳辉——糖尿病足处理的临床路径

在2015年国际腔内血管学大会,来自华中科技大学同济医学院附属梨园医院的李炳辉主任为我们介绍了糖尿病足处理的临床路径。 糖尿病足坏疽是糖尿病最常见且较严重的并发症之一,有截肢及威胁患者生命的可能。作为临床医生,需明确认识危险因素,及时有效的对患者进行治疗;需多学科团队合作,降低下肢截肢的风险;若发生截肢,应明确截肢平面,尽量保障肢体功能。 初步病情评估:

“糖尿病足”可增加患者认知功能障碍的风险!

糖尿病足增加民众认知障碍风险

Diabetes care:抗生素是糖尿病足骨髓炎治疗的**

目前,尚无前瞻性试验研究在糖尿病足骨髓炎患者中比单用抗生素治疗与外科手术治疗。 为此,来自西班牙马德里康普顿斯大学的Lázaro-Martínez教授及其团队进行了一项研究,对单用抗生素治疗和接受保守手术治疗的糖尿病足骨髓炎患者的治疗结局进行比较,并在治愈后对患者进行12周随访。该研究结果发表在2014年03月的Diabetes care杂志上。【原文下载】 该研究是马德里康普顿斯大学

许樟荣:糖尿病足疾病临床研究质量亟待提高

在9月13日召开的2013年中国糖尿病足及相关疾病论坛上,大会执行主席、中华医学会糖尿病学分会糖尿病足与周围血管病学组组长许樟荣教授在大会开幕式上发表主旨演讲时指出,我国的糖尿病足疾病已经越来越受到医务人员的重视,有关论文的发表数量也明显增加。但是临床工作的深入和临床研究质量的提高是迫切需要解决的关键性问题。 许教授指出,糖尿病足是糖尿病的主要慢性并发症之一,糖尿病足

Baidu
map
Baidu
map
Baidu
map